Alessandro Doria

List of Publications by Year in Descending Order

163 papers	12,341 citations	48 h-index	109 g-index
171 ext. papers	14,362 ext. citations	9.2 avg, IF	5.75 L-index

#	Paper	IF	Citations
163	Diabetes and Myocardial Fibrosis: A Systematic Review and Meta-Analysis.. *JACC: Cardiovascular Imaging*, **2022**, 15, 796-808	8.4	2
162	Contribution of rare variants in monogenic diabetes-genes to early-onset type 2 diabetes.. *Diabetes and Metabolism*, **2022**, 101353	5.4	0
161	Diabetes mellitus correlates with increased biological age as indicated by clinical biomarkers. *GeroScience*, **2021**, 1	8.9	4
160	Gain of function of Malate Dehydrogenase 2 (MDH2) and familial hyperglycemia. *Journal of Clinical Endocrinology and Metabolism*, **2021**,	5.6	1
159	A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment. *Diabetes Care*, **2021**, 44, 1410-1418	14.6	2
158	A New Panel-Estimated GFR, Including β-Microglobulin and β-Trace Protein and Not Including Race, Developed in a Diverse Population. *American Journal of Kidney Diseases*, **2021**, 77, 673-683.e1	7.4	16
157	Comprehensive Search for Novel Circulating miRNAs and Axon Guidance Pathway Proteins Associated with Risk of ESKD in Diabetes. *Journal of the American Society of Nephrology: JASN*, **2021**, 32, 2331-2351	12.7	3
156	Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial. *Diabetes Care*, **2021**, 44, 164-173	14.6	12
155	Autosomal dominant diabetes associated with a novel ZYG11A mutation resulting in cell cycle arrest in beta-cells. *Molecular and Cellular Endocrinology*, **2021**, 522, 111126	4.4	2
154	New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. *New England Journal of Medicine*, **2021**, 385, 1737-1749	59.2	125
153	Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. *New England Journal of Medicine*, **2020**, 382, 2493-2503	59.2	100
152	Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid. *Diabetes*, **2020**, 69, 771-783	0.9	12
151	The core clock gene, Bmal1, and its downstream target, the SNARE regulatory protein secretagogin, are necessary for circadian secretion of glucagon-like peptide-1. *Molecular Metabolism*, **2020**, 31, 124-137	8.8	17
150	Association of the 1q25 Diabetes-Specific Coronary Heart Disease Locus With Alterations of the γ-Glutamyl Cycle and Increased Methylglyoxal Levels in Endothelial Cells. *Diabetes*, **2020**, 69, 2206-2216	0.9	4
149	Uric acid and risk of diabetic kidney disease. *Journal of Nephrology*, **2020**, 33, 995-999	4.8	5
148	Disentangling the heterogeneity of adulthood-onset non-autoimmune diabetes: a little closer but lot more to do. *Current Opinion in Pharmacology*, **2020**, 55, 157-164	5.1	3
147	Insufficient Evidence for Interaction Between Haptoglobin Phenotypes and Intensive Glycemic Control on Cardiovascular Outcomes. *Journal of the American College of Cardiology*, **2020**, 75, 2995-2996	15.1	

146	A Genetic Locus on Chromosome 2q24 Predicting Peripheral Neuropathy Risk in Type 2 Diabetes: Results From the ACCORD and BARI 2D Studies. *Diabetes*, **2019**, 68, 1649-1662	0.9	15
145	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data. *Diabetes Care*, **2019**, 42, 1454-1463	14.6	28
144	A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. *Nature Medicine*, **2019**, 25, 805-813	50.5	136
143	Loss-of-Function Mutation in Thiamine Transporter 1 in a Family With Autosomal Dominant Diabetes. *Diabetes*, **2019**, 68, 1084-1093	0.9	9
142	Estimation of Mortality Risk in Type 2 Diabetic Patients (ENFORCE): An Inexpensive and Parsimonious Prediction Model. *Journal of Clinical Endocrinology and Metabolism*, **2019**, 104, 4900-4908	5.6	10
141	Leveraging Genetics to Improve Cardiovascular Health in Diabetes: The 2018 Edwin Bierman Award Lecture. *Diabetes*, **2019**, 68, 479-489	0.9	2
140	Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus. *Circulation*, **2019**, 139, 730-743	16.7	39
139	Genetic Variants in and Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. *Diabetes*, **2018**, 67, 1428-1440	0.9	18
138	Uric Acid and Diabetic Nephropathy Risk. *Contributions To Nephrology*, **2018**, 192, 103-109	1.6	19
137	Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes. *Clinical Pharmacology and Therapeutics*, **2018**, 103, 712-721	6.1	20
136	Malate Dehydrogenase 2 (MDH2) as a New Diabetogene Causing Hyperglycemia in Families with Multigenerational Diabetes. *Diabetes*, **2018**, 67, 262-OR	0.9	1
135	Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD. *Diabetes Care*, **2018**, 41, 348-355	14.6	10
134	Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial. *Diabetes Care*, **2018**, 41, 2404-2413	14.6	16
133	Insulin Signaling Regulates the FoxM1/PLK1/CENP-A Pathway to Promote Adaptive Pancreatic β Cell Proliferation. *Cell Metabolism*, **2017**, 25, 868-882.e5	24.6	60
132	Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease. *Kidney International*, **2017**, 92, 258-266	9.9	29
131	Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial. *Diabetes Care*, **2016**, 39, 1915-1924	14.6	32
130	Genetics of Diabetic Micro- and Macrovascular Complications **2016**, 153-180		
129	SerpinB1 Promotes Pancreatic β Cell Proliferation. *Cell Metabolism*, **2016**, 23, 194-205	24.6	132

128	CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease. *Diabetologia*, **2016**, 59, 21-29	10.3	18
127	Variants in ANGPTL4 and the Risk of Coronary Artery Disease. *New England Journal of Medicine*, **2016**, 375, 2305-2306	59.2	8
126	Dissecting diabetes/metabolic disease mechanisms using pluripotent stem cells and genome editing tools. *Molecular Metabolism*, **2015**, 4, 593-604	8.8	22
125	Genetic Variant at the GLUL Locus Predicts All-Cause Mortality in Patients With Type 2 Diabetes. *Diabetes*, **2015**, 64, 2658-63	0.9	18
124	Infrequent TRIB3 coding variants and coronary artery disease in type 2 diabetes. *Atherosclerosis*, **2015**, 242, 334-9	3.1	7
123	Loss-of-Function Mutations in APPL1 in Familial Diabetes Mellitus. *American Journal of Human Genetics*, **2015**, 97, 177-85	11	91
122	Activation of human brown adipose tissue by a β-adrenergic receptor agonist. *Cell Metabolism*, **2015**, 21, 33-8	24.6	632
121	Serum resistin and glomerular filtration rate in patients with type 2 diabetes. *PLoS ONE*, **2015**, 10, e0119529	3.7	10
120	Joint effect of insulin signaling genes on all-cause mortality. *Atherosclerosis*, **2014**, 237, 639-44	3.1	7
119	Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. *Diabetes Care*, **2014**, 37, 226-34	14.6	168
118	Serum resistin, cardiovascular disease and all-cause mortality in patients with type 2 diabetes. *PLoS ONE*, **2014**, 8, e64729	3.7	63
117	Association between a genetic variant related to glutamic acid metabolism and coronary heart disease in individuals with type 2 diabetes. *JAMA - Journal of the American Medical Association*, **2013**, 310, 821-8	27.4	95
116	Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. *Current Diabetes Reports*, **2013**, 13, 550-9	5.6	120
115	The SH2B1 obesity locus and abnormal glucose homeostasis: lack of evidence for association from a meta-analysis in individuals of European ancestry. *Nutrition, Metabolism and Cardiovascular Diseases*, **2013**, 23, 1043-9	4.5	5
114	Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects. *Cardiovascular Diabetology*, **2013**, 12, 119	8.7	16
113	Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance. *Nature Medicine*, **2013**, 19, 217-26	50.5	54
112	Joint effect of insulin signaling genes on cardiovascular events and on whole body and endothelial insulin resistance. *Atherosclerosis*, **2013**, 226, 140-5	3.1	17
111	Joint effect of insulin signaling genes on insulin secretion and glucose homeostasis. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, E1143-7	5.6	13

110	The IRS1 G972R polymorphism and glomerular filtration rate in patients with type 2 diabetes of European ancestry. *Nephrology Dialysis Transplantation*, **2013**, 28, 3031-4	4.3	2
109	Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes. *Diabetes*, **2013**, 62, 3589-98	0.9	95
108	Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy?. *Seminars in Nephrology*, **2012**, 32, 437-44	4.8	26
107	Genetic prediction of common diseases. Still no help for the clinical diabetologist!. *Nutrition, Metabolism and Cardiovascular Diseases*, **2012**, 22, 929-36	4.5	16
106	Serum resistin and kidney function: a family-based study in non-diabetic, untreated individuals. *PLoS ONE*, **2012**, 7, e38414	3.7	23
105	Genetic predisposition to dyslipidemia and type 2 diabetes risk in two prospective cohorts. *Diabetes*, **2012**, 61, 745-52	0.9	60
104	The 9p21 coronary artery disease locus and kidney dysfunction in patients with Type 2 diabetes mellitus. *Nephrology Dialysis Transplantation*, **2012**, 27, 4411-3	4.3	5
103	Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. *Journal of the American Society of Nephrology: JASN*, **2012**, 23, 507-15	12.7	307
102	Genetic susceptibility to coronary heart disease in type 2 diabetes: 3 independent studies. *Journal of the American College of Cardiology*, **2011**, 58, 2675-82	15.1	68
101	The type 2 diabetes and insulin-resistance locus near IRS1 is a determinant of HDL cholesterol and triglycerides levels among diabetic subjects. *Atherosclerosis*, **2011**, 216, 157-60	3.1	22
100	The SH2B1 obesity locus is associated with myocardial infarction in diabetic patients and with NO synthase activity in endothelial cells. *Atherosclerosis*, **2011**, 219, 667-72	3.1	16
99	Increased prevalence of proliferative retinopathy in patients with type 1 diabetes who are deficient in glucose-6-phosphate dehydrogenase. *Diabetologia*, **2011**, 54, 1539-42	10.3	32
98	The ENPP1 Q121 variant predicts major cardiovascular events in high-risk individuals: evidence for interaction with obesity in diabetic patients. *Diabetes*, **2011**, 60, 1000-7	0.9	33
97	Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the joslin 50-year medalist study. *Diabetes Care*, **2011**, 34, 968-74	14.6	174
96	GRB10 gene and type 2 diabetes in Whites. *Journal of Internal Medicine*, **2010**, 267, 132-3	10.8	6
95	A functional variant in the gene 3Quntranslated region regulates HSP70 expression and is a potential candidate for insulin resistance-related abnormalities. *Journal of Internal Medicine*, **2010**, 267, 237-40	10.8	3
94	Circulating high molecular weight adiponectin isoform is heritable and shares a common genetic background with insulin resistance in nondiabetic White Caucasians from Italy: evidence from a family-based study. *Journal of Internal Medicine*, **2010**, 267, 287-94	10.8	36
93	High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up. *Diabetes Care*, **2010**, 33, 1337-43	14.6	167

92	Designing and implementing sample and data collection for an international genetics study: the Type 1 Diabetes Genetics Consortium (T1DGC). *Clinical Trials*, **2010**, 7, S5-S32	2.2	24
91	Residual insulin production and pancreatic Ecell turnover after 50 years of diabetes: Joslin Medalist Study. *Diabetes*, **2010**, 59, 2846-53	0.9	352
90	Genetics of diabetes complications. *Current Diabetes Reports*, **2010**, 10, 467-75	5.6	42
89	Mutations at the BLK locus linked to maturity onset diabetes of the young and beta-cell dysfunction. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 14460-5	11.5	123
88	Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. *Diabetes*, **2009**, 58, 1403-10	0.9	227
87	The TRIB3 Q84R polymorphism and risk of early-onset type 2 diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 190-6	5.6	49
86	The role of HSP70 on ENPP1 expression and insulin-receptor activation. *Journal of Molecular Medicine*, **2009**, 87, 139-144	5.5	13
85	IRS1 G972R polymorphism and type 2 diabetes: a paradigm for the difficult ascertainment of the contribution to disease susceptibility of Qow-frequency-low-riskQvariants. *Diabetologia*, **2009**, 52, 1852-7	10.3	30
84	Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. *Nature Medicine*, **2009**, 15, 940-5	50.5	582
83	Association of the Q121 variant of ENPP1 gene with decreased kidney function among patients with type 2 diabetes. *American Journal of Kidney Diseases*, **2009**, 53, 273-80	7.4	16
82	Identification and importance of brown adipose tissue in adult humans. *New England Journal of Medicine*, **2009**, 360, 1509-17	59.2	3046
81	Genome-wide linkage screen for stature and body mass index in 3.032 families: evidence for sex- and population-specific genetic effects. *European Journal of Human Genetics*, **2009**, 17, 258-66	5.3	12
80	Identification and Importance of Brown Adipose Tissue in Adult Humans. *Obstetrical and Gynecological Survey*, **2009**, 64, 519-520	2.4	15
79	A polymorphism at the IL6ST (gp130) locus is associated with traits of the metabolic syndrome. *Obesity*, **2008**, 16, 205-10	8	14
78	The emerging genetic architecture of type 2 diabetes. *Cell Metabolism*, **2008**, 8, 186-200	24.6	239
77	Identification of a locus modulating serum C-reactive protein levels on chromosome 5p15. *Atherosclerosis*, **2008**, 196, 863-70	3.1	8
76	Variants in the CD36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterol. *Human Molecular Genetics*, **2008**, 17, 1695-704	5.6	144
75	Interaction between poor glycemic control and 9p21 locus on risk of coronary artery disease in type 2 diabetes. *JAMA - Journal of the American Medical Association*, **2008**, 300, 2389-97	27.4	92

74	A hierarchical and modular approach to the discovery of robust associations in genome-wide association studies from pooled DNA samples. *BMC Genetics*, **2008**, 9, 6	2.6	17
73	Cathepsin L activity controls adipogenesis and glucose tolerance. *Nature Cell Biology*, **2007**, 9, 970-7	23.4	120
72	Glutamine to arginine substitution at amino acid 84 of mammalian tribbles homolog TRIB3 and CKD in whites with type 2 diabetes. *American Journal of Kidney Diseases*, **2007**, 50, 688-9	7.4	14
71	Mutations in the SLC30A8 gene are not a major cause of MODY or other forms of early-onset, autosomal dominant type 2 diabetes. *Diabetologia*, **2007**, 50, 2224-6	10.3	7
70	Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study. *Diabetes Care*, **2007**, 30, 1995-7	14.6	138
69	Tag polymorphisms at the A20 (TNFAIP3) locus are associated with lower gene expression and increased risk of coronary artery disease in type 2 diabetes. *Diabetes*, **2007**, 56, 499-505	0.9	62
68	Variations in adiponectin receptor genes and susceptibility to type 2 diabetes in women: a tagging-single nucleotide polymorphism haplotype analysis. *Diabetes*, **2007**, 56, 1586-91	0.9	16
67	PAX4 mutations in Thais with maturity onset diabetes of the young. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 2821-6	5.6	120
66	Why type 2 diabetes is not an equal opportunity disease: recent progress in genetics. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2007**, 10, 389-390	3.8	0
65	Genetic variability at the leptin receptor (LEPR) locus is a determinant of plasma fibrinogen and C-reactive protein levels. *Atherosclerosis*, **2007**, 191, 121-7	3.1	36
64	Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. *Diabetes*, **2007**, 56, 1198-209	0.9	230
63	Heritability of serum resistin and its genetic correlation with insulin resistance-related features in nondiabetic Caucasians. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 2792-5	5.6	108
62	Adiponectin genetic variability, plasma adiponectin, and cardiovascular risk in patients with type 2 diabetes. *Diabetes*, **2006**, 55, 1512-6	0.9	110
61	Common haplotypes at the adiponectin receptor 1 (ADIPOR1) locus are associated with increased risk of coronary artery disease in type 2 diabetes. *Diabetes*, **2006**, 55, 2763-70	0.9	37
60	Examination of PPP1R3B as a candidate gene for the type 2 diabetes and MODY loci on chromosome 8p23. *Annals of Human Genetics*, **2006**, 70, 587-93	2.2	19
59	A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes. *Obesity*, **2006**, 14, 2119-26	8	58
58	Association of hGrb10 genetic variations with type 2 diabetes in Caucasian subjects. *Diabetes Care*, **2006**, 29, 1181-3	14.6	9
57	Lack of evidence for interaction between APM1 and PPARgamma2 genes in modulating insulin sensitivity in nondiabetic Caucasians from Italy. *Journal of Internal Medicine*, **2005**, 257, 315-7	10.8	4

56	A common haplotype at the CD36 locus is associated with high free fatty acid levels and increased cardiovascular risk in Caucasians. *Human Molecular Genetics*, **2005**, 14, 3973-3973	5.6	4
55	The K121Q polymorphism of the ENPP1/PC-1 gene is associated with insulin resistance/atherogenic phenotypes, including earlier onset of type 2 diabetes and myocardial infarction. *Diabetes*, **2005**, 54, 3021-5	0.9	96
54	The +276 polymorphism of the APM1 gene, plasma adiponectin concentration, and cardiovascular risk in diabetic men. *Diabetes*, **2005**, 54, 1607-10	0.9	122
53	Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products. *Diabetes and Vascular Disease Research*, **2005**, 2, 81-7	3.3	41
52	Fatty acid translocase (FAT/CD36) is localized on insulin-containing granules in human pancreatic beta-cells and mediates fatty acid effects on insulin secretion. *Diabetes*, **2005**, 54, 472-81	0.9	74
51	Identification of a locus for maturity-onset diabetes of the young on chromosome 8p23. *Diabetes*, **2004**, 53, 1375-84	0.9	41
50	Genetic variation at the adiponectin locus and risk of type 2 diabetes in women. *Diabetes*, **2004**, 53, 209-13	0.9	97
49	The +276 G/T single nucleotide polymorphism of the adiponectin gene is associated with coronary artery disease in type 2 diabetic patients. *Diabetes Care*, **2004**, 27, 2015-20	14.6	114
48	Multigenic control of serum adiponectin levels: evidence for a role of the APM1 gene and a locus on 14q13. *Physiological Genomics*, **2004**, 19, 170-4	3.6	64
47	Elevated C-reactive protein levels do not correspond to autoimmunity in type 1 diabetes. *Diabetes Care*, **2004**, 27, 2769-70	14.6	13
46	A common haplotype at the CD36 locus is associated with high free fatty acid levels and increased cardiovascular risk in Caucasians. *Human Molecular Genetics*, **2004**, 13, 2197-205	5.6	141
45	Adipokine genes and the insulin-resistance syndrome. *International Congress Series*, **2003**, 1253, 63-71		
44	Genetic modifiers of the age at diagnosis of diabetes (MODY3) in carriers of hepatocyte nuclear factor-1alpha mutations map to chromosomes 5p15, 9q22, and 14q24. *Diabetes*, **2003**, 52, 2182-6	0.9	33
43	Genetic variants at the resistin locus and risk of type 2 diabetes in Caucasians. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 4407-10	5.6	77
42	Genetic variability in insulin action inhibitor Ikkbeta (IKBKB) does not play a major role in the development of type 2 diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 1894-7	5.6	
41	A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. *Diabetes*, **2002**, 51, 2306-12	0.9	372
40	Determinants of the development of diabetes (maturity-onset diabetes of the young-3) in carriers of HNF-1alpha mutations: evidence for parent-of-origin effect. *Diabetes Care*, **2002**, 25, 2292-301	14.6	65
39	Type 2 diabetes locus on 12q15. Further mapping and mutation screening of two candidate genes. *Diabetes*, **2001**, 50, 204-8	0.9	22

38	Mutation screening of the neurogenin-3 gene in autosomal dominant diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 2320-2	5.6	9
37	Mutation Screening of the Neurogenin-3 Gene in Autosomal Dominant Diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 2320-2322	5.6	5
36	Recent advances in the genetics of maturity-onset diabetes of the young and other forms of autosomal dominant diabetes. *Current Opinion in Endocrinology, Diabetes and Obesity*, **2000**, 7, 203-210		13
35	Hepatocyte nuclear factor-4gamma: cDNA sequence, gene organization, and mutation screening in early-onset autosomal-dominant type 2 diabetes. *Diabetes*, **1999**, 48, 2099-102	0.9	26
34	Exclusion of insulin receptor substrate 2 (IRS-2) as a major locus for early-onset autosomal dominant type 2 diabetes. *Diabetes*, **1999**, 48, 640-2	0.9	38
33	Evidence of a novel type 2 diabetes locus 50 cM centromeric to NIDDM2 on chromosome 12q. *Diabetes*, **1999**, 48, 2246-51	0.9	41
32	Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. *Nature Genetics*, **1999**, 23, 323-8	36.3	488
31	The role of aldose reductase gene in the susceptibility to diabetic nephropathy in Type II (non-insulin-dependent) diabetes mellitus. *Diabetologia*, **1999**, 42, 94-7	10.3	45
30	Phenotypic characteristics of early-onset autosomal-dominant type 2 diabetes unlinked to known maturity-onset diabetes of the young (MODY) genes. *Diabetes Care*, **1999**, 22, 253-61	14.6	44
29	An association between NIDDM and a GAA trinucleotide repeat polymorphism in the X25/frataxin (Friedreich's ataxia) gene. *Diabetes*, **1998**, 47, 851-4	0.9	32
28	Genetic markers of increased susceptibility to diabetic nephropathy. *Hormone Research in Paediatrics*, **1998**, 50 Suppl 1, 6-11	3.3	6
27	Synergistic effect of angiotensin II type 1 receptor genotype and poor glycaemic control on risk of nephropathy in IDDM. *Diabetologia*, **1997**, 40, 1293-9	10.3	48
26	Molecular cloning of the human rad gene: gene structure and complete nucleotide sequence. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **1996**, 1316, 145-8	6.9	5
25	Genetics of non-insulin-dependent (type-II) diabetes mellitus. *Annual Review of Medicine*, **1996**, 47, 509-31	17.4	174
24	Angiotensinogen polymorphism M235T, hypertension, and nephropathy in insulin-dependent diabetes. *Hypertension*, **1996**, 27, 1134-9	8.5	40
23	Codon 972 polymorphism in the insulin receptor substrate-1 gene, obesity, and risk of noninsulin-dependent diabetes mellitus. *Journal of Clinical Endocrinology and Metabolism*, **1996**, 81, 1657-1659	5.6	40
22	Diabetes susceptibility at IDDM2 cannot be positively mapped to the VNTR locus of the insulin gene. *Diabetologia*, **1996**, 39, 594-599	10.3	
21	Genetic susceptibility to nephropathy in insulin-dependent diabetes: from epidemiology to molecular genetics. *Diabetes/metabolism Reviews*, **1995**, 11, 287-314		35

20	Activity and expression of the Na+/H+ exchanger in human endothelial cells cultured in high glucose. *Diabetologia*, **1995**, 38, 785-91	10.3	17
19	Trinucleotide repeats at the rad locus. Allele distributions in NIDDM and mapping to a 3-cM region on chromosome 16q. *Diabetes*, **1995**, 44, 243-247	0.9	8
18	DdeI polymorphism in the AGTR1 gene. *Human Molecular Genetics*, **1994**, 3, 1444	5.6	21
17	Angiotensin I-converting enzyme (ACE): estimation of DNA haplotypes in unrelated individuals using denaturing gradient gel blots. *Human Genetics*, **1994**, 94, 117-23	6.3	14
16	Molecular characterization of a DDEI melting polymorphism at the angiotensin I-converting enzyme (ACE) locus. *Human Mutation*, **1994**, 4, 155-7	4.7	4
15	Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I--converting enzyme gene. *Diabetes*, **1994**, 43, 690-695	0.9	40
14	Four RSAI restriction fragment melting polymorphisms in the region of the insulin receptor gene encoding for the alpha subunit. *Clinical Genetics*, **1993**, 44, 279-80	4	1
13	Lipoprotein compositional abnormalities in type 1 (insulin-dependent) diabetic patients. *Acta Diabetologica*, **1993**, 30, 11-6	3.9	9
12	Molecular methods for the study of the genetic determinants of nephropathy in type 1 (insulin-dependent) diabetes. *Acta Diabetologica*, **1992**, 29, 136-141	3.9	1
11	Clustering of risk factors in hypertensive insulin-dependent diabetics with high sodium-lithium countertransport. *Kidney International*, **1992**, 41, 855-61	9.9	43
10	Myocardial metabolism in type 1 diabetic patients without coronary artery disease. *Diabetic Medicine*, **1991**, 8 Spec No, S104-7	3.5	25
9	Ketone body kinetics in vivo using simultaneous administration of acetoacetate and 3-hydroxybutyrate labelled with stable isotopes. *Acta Diabetologica Latina*, **1990**, 27, 41-51		5
8	Substrate availability other than glucose in the brain during euglycemia and insulin-induced hypoglycemia in dogs. *Metabolism: Clinical and Experimental*, **1990**, 39, 46-50	12.7	18
7	Ketone body metabolism: a physiological and clinical overview. *Diabetes/metabolism Reviews*, **1989**, 5, 299-319		22
6	Kidney hemodynamics after ketone body and amino acid infusion in normal and IDDM subjects. *Diabetes*, **1989**, 38, 75-83	0.9	7
5	Type I insulin-dependent diabetic patients show an impaired renal hemodynamic response to protein intake. *The Journal of Diabetic Complications*, **1988**, 2, 27-9		1
4	Porcine and human insulin absorption from subcutaneous tissues in normal and insulin-dependent diabetic subjects: a deconvolution-based approach. *Journal of Clinical Endocrinology and Metabolism* , **1988**, 67, 551-9	5.6	13
3	Glomerular filtration rate is increased in man by the infusion of both D,L-3-hydroxybutyric acid and sodium D,L-3-hydroxybutyrate. *Journal of Clinical Endocrinology and Metabolism*, **1987**, 65, 331-8	5.6	24

2	Glucose and ketone body turnover in carnitine-palmitoyl-transferase deficiency. *Metabolism: Clinical and Experimental*, **1987**, 36, 821-6	12.7	3
1	Ketone bodies increase glomerular filtration rate in normal man and in patients with type 1 (insulin-dependent) diabetes mellitus. *Diabetologia*, **1987**, 30, 214-21	10.3	29